NoticeThis is an independent non-profit initiative. We are not affiliated with the European Medicines Agency (EMA) or the official CTIS system. For the official EU Clinical Trials Information System, visit:
EMA Registry →
Subjects with Aadvanced solid tumors for whom life-prolonging therapies do not exist or available therapies are intolerable or no longer effective. Single-agent XB002 will be evaluated up to 10 tumor types, and combination treatment will also be evaluated with nivolumab in NSCLC, SCCHN, and esophageal SCC, and for XB002 plus bevacizumab in EOC.
1 total trials
Filter these 1 trials by phase, country, sponsor and more.